Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Filings indexed 317 across all filing types
Latest filing 2026-05-15 Director's Dealing
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 90% confidence The document announces notifications of transactions by persons discharging managerial responsibilities (PDMRs), detailing vesting and settlement of RSUs and equity incentive awards granted to directors. This is a report of insider dealings by company directors. According to the filing definitions, this falls under Director's Dealing (Code: DIRS).
2026-05-15 English
Oculis birtir niðurstöður aðalfundar 2026 og tilkynnir um kjör Gregory D. Perry í stjórn félagsins
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release that discloses the official results of the 2026 Annual General Meeting, including vote outcomes on resolutions and the election of a new board member. This aligns with a Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Icelandic
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the results of the 2026 Annual General Meeting, including vote approvals of agenda items, election of board members, discharge of directors, compensation approvals, capital band amendments, and Articles of Association changes. It provides detailed voting outcomes and rights-related resolutions rather than the report itself or financial statements full text. This matches the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-14 English
6-K
Foreign Filer Report
2026-05-14 English
Oculis birtir uppgjör fyrir fyrsta ársfjórðung 2026 og kynnir áfanga í rekstri félagsins
Interim / Quarterly Report Classification · 93% confidence The document is a detailed first quarter report for the period ending March 31, 2026, issued via GlobeNewswire. It includes narrative management commentary on clinical milestones and pipeline progress, and—importantly—full condensed consolidated financial statements (balance sheet and statement of loss) with line-by-line figures for assets, liabilities, equity, expenses, and net loss per share. This goes beyond a brief earnings release (ER) and contains substantive financial data and analysis, fitting the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-11 Icelandic
Oculis Reports Q1 2026 Financial Results and Provides Company Update
Earnings Release Classification · 92% confidence The document is a press release announcing first-quarter 2026 financial results, complete with key highlights (cash runway, R&D and G&A expenses, net loss) and condensed consolidated statements. It is not a full annual report or a notice of a report being published; it is the initial earnings announcement for Q1. Therefore, it fits the definition of an Earnings Release. Q1 2026
2026-05-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.